How should I manage a 60-year-old woman with type 2 diabetes on glimepiride, teneligliptin, metformin, and empagliflozin who presents with 4–5 days of generalized myalgia, hyperglycemia, normal oxygen saturation, normal heart rate, and normal blood pressure during a seasonal influenza outbreak?

Immediate Management Approach

Temporarily discontinue metformin and empagliflozin immediately, start empiric oseltamivir 75 mg twice daily for 5 days, check blood lactate and ketones, and transition to basal-bolus insulin for acute glycemic control during this illness. 1, 2, 3

Critical Safety Concerns During Acute Illness

Metformin Must Be Stopped

The patient's generalized myalgia is a red flag symptom for metformin-associated lactic acidosis, which presents with nonspecific symptoms including malaise, myalgias, and abdominal pain 3. During acute illness with potential influenza:

• Metformin increases lactic acidosis risk through decreased liver lactate uptake and impaired clearance 3
• Acute illness creates hypoxic states and potential volume depletion that dramatically increase this risk 3
• The FDA label explicitly warns to discontinue metformin in patients at risk for lactic acidosis, including those with acute illness 3

Immediate action: Check serum lactate level. If elevated (>2 mmol/L), this is a medical emergency requiring hospitalization 3.

SGLT2 Inhibitor (Empagliflozin) Risks

Stop empagliflozin during acute illness because:

• Euglycemic diabetic ketoacidosis risk increases with poor oral intake during illness 2
• Current hyperglycemia (RBS 311 mg/dL) with potential ketosis creates dangerous conditions 2
• Check urine or serum ketones immediately 2

Sulfonylurea (Glimepiride) Considerations

Continue glimepiride cautiously but reduce dose by 50% (to 0.5 mg daily) because:

• Risk of sustained hypoglycemia during acute illness with variable food intake 2, 4
• Multiple drug interactions during illness can potentiate hypoglycemic effects 4

Influenza Management

Start Antiviral Treatment Immediately

Begin oseltamivir 75 mg orally twice daily for 5 days without waiting for testing 1. This patient qualifies for treatment because:

• Age 60 years (high-risk category) 1
• Chronic medical condition (diabetes) requiring treatment regardless of symptom duration 1
• Presenting during seasonal influenza outbreak with compatible symptoms (myalgia, 4-5 days duration) 1
• Treatment should start "as soon as possible" even on day 4-5 of symptoms in high-risk patients 1

Monitoring for Complications

Watch for bacterial superinfection if patient:

• Fails to improve after 3-5 days of antiviral treatment 1
• Develops fever, respiratory symptoms, or deteriorates after initial improvement 1

Acute Glycemic Management

Transition to Insulin Temporarily

Implement basal-bolus insulin regimen during acute illness 2:

• Basal insulin: Start glargine or detemir 0.2 units/kg/day (approximately 10-12 units for average 60 kg female)
• Bolus insulin: Rapid-acting insulin with meals, starting 4-6 units per meal
• Correction scale: Add supplemental rapid-acting insulin for glucose >180 mg/dL

Rationale: The guideline explicitly recommends basal-plus approach for patients with diabetes during acute illness, and current RBS of 311 mg/dL indicates inadequate control requiring insulin 2.

Continue Teneligliptin

Keep teneligliptin 20 mg daily - this is the safest oral agent to continue:

• Low hypoglycemia risk 5
• No contraindications during acute illness 2
• Provides modest glycemic benefit without metabolic acidosis risk 5

Specific Monitoring Parameters

Within 24 hours, check:

• Serum lactate (critical for metformin safety) 3
• Serum or urine ketones (SGLT2i safety) 2
• Basic metabolic panel including creatinine/eGFR 3
• Complete blood count (if bacterial coinfection suspected) 1

Daily monitoring:

• Capillary blood glucose 4 times daily (fasting, pre-meals, bedtime)
• Vital signs including oxygen saturation
• Symptom progression (respiratory symptoms, fever, worsening myalgia)

When to Resume Oral Agents

After illness resolution (typically 7-10 days):

• Restart metformin only after confirming normal renal function (eGFR >45 mL/min/1.73m²) and patient eating/drinking normally 3
• Restart empagliflozin after confirming adequate oral intake and negative ketones 2
• Increase glimepiride back to 1 mg if no hypoglycemia occurred
• Transition off insulin gradually as oral agents resume, monitoring glucose closely

Critical Pitfalls to Avoid

1. Do not continue metformin during acute illness - the combination of myalgia symptoms plus acute illness creates unacceptable lactic acidosis risk 3
2. Do not delay antiviral treatment - this high-risk patient benefits even on day 4-5 of symptoms 1
3. Do not use sliding scale insulin alone - this patient has poor baseline control (RBS 311) requiring basal insulin 2
4. Do not restart SGLT2i until eating normally - risk of ketoacidosis persists with poor intake 2